Study of C.E.R.A. for Anemia in Lung Cancer Patients
Author Information
Author(s): Hirsh Vera, Glaspy John, Mainwaring Paul, Manegold Christian, Ramlau Rodryg, Eid Joseph E
Primary Institution: Royal Victoria Hospital, McGill University Health Center, Montreal, Quebec, Canada
Hypothesis
Does C.E.R.A. improve hemoglobin levels in anemic patients with advanced non-small cell lung cancer receiving chemotherapy?
Conclusion
C.E.R.A. showed clinical activity and safety in patients with NSCLC, with dose-dependent increases in hemoglobin responses.
Supporting Evidence
- C.E.R.A. was generally well tolerated.
- 51% and 62% of patients in the 4.2 and 6.3 μg/kg Q3W groups achieved a hematopoietic response.
- 64% to 85% of patients remained transfusion-free during the study.
- The mean duration on study was similar across the six dose groups (74–81 days).
- Anemia has a major impact on the quality of life of patients with cancer.
Takeaway
This study tested a new medicine called C.E.R.A. to help people with lung cancer who are anemic, and it found that it can help increase their blood levels.
Methodology
This was a Phase II, randomized, open-label, multicenter, dose-finding study with patients receiving C.E.R.A. subcutaneously for 12 weeks.
Potential Biases
Potential bias due to lack of blinding and the open-label design.
Limitations
The study lacked a placebo or active control group and did not allow dose increases for inadequate hemoglobin response.
Participant Demographics
Patients were adults with Stage IIIB or IV NSCLC and a hemoglobin level of ≤ 11 g/dL.
Statistical Information
Confidence Interval
95% CI: -0.66 to +0.59
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website